Business & Finance
Sonoma Biotherapeutics Enters Long-Term Lease Agreement to Establish a Treg Cell Therapy R and D and Manufacturing Center
26 August 2022 - - US-based biotechnology company Sonoma Biotherapeutics, Inc has entered into a lease agreement to develop an approximately 83,000 square-foot Research and Development and Manufacturing Center to expand its operations in Seattle and complement its existing R and D enterprise in South San Francisco, the company said.

The Center will support the R and D and manufacturing of Sonoma Bio's pipeline of gene-modified Treg therapies for autoimmune and inflammatory diseases at scale.

This R and D and Manufacturing Center will include the development and use of technologies and capabilities from cell selection and genetic modification to intelligent manufacturing automation and information technology systems.

The integration of this infrastructure and scientific expertise will enable Sonoma Bio to move efficiently from molecular target identification to in-house full-scale production for multiple product candidates and indications in Phase 2 clinical trials and beyond.

The Center will be located on the Seattle waterfront at 501 Elliott Avenue West, a property owned by Office Properties Income Trust and being redeveloped by The RMR Group into Unison Elliott Bay.

Sonoma Biotherapeutics is a clinical-stage biotechnology company developing engineered regulatory T cell therapies to treat serious autoimmune and inflammatory diseases by restoring balance to the immune system.

Sonoma Biotherapeutics is based in South San Francisco and Seattle.